Amneal Pharmaceuticals (AMRX Quick QuoteAMRX - Free Report) reported $862.68 million in revenue for the quarter ended September 2026, representing a year-over-year increase of 10%. EPS of $0.26 for the same period compares to $0.17 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $818.22 million, representing a surprise of +5.44%. The company delivered an EPS surprise of +8.33%, with the consensus EPS estimate being $0.24.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Amneal performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Revenue- Affordable Medicines Segment: $547.11 million versus $500.03 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +18.8% change.
• Net Revenue- AvKARE Segment: $165.31 million compared to the $169.03 million average estimate based on three analysts. The reported number represents a change of -16.7% year over year.
• Net Revenue- Specialty Segment: $150.26 million versus the three-analyst average estimate of $149.17 million. The reported number represents a year-over-year change of +20%.

View all Key Company Metrics for Amneal here>>>

Shares of Amneal have returned +0.4% over the past month versus the Zacks S&P 500 composite's -2.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.